EntreMed (ENMD) Initiates ENMD-2076 Phase 2
- Top 10 News for 8/25 - 8/29: S&P 500's New Record; U.S. Q2 GDP Outpaces Views; Major Mergers Aplenty
- Pressure on U.S. to Update Terror Alert System After U.K. Raises Terror Threat Level
- American Airlines Group (AAL)/Orbitz Worldwide (OWW) Reach Agreement; American Airlines Back on Orbitz Sites
- FTC Requests Additional Info from Reynolds American (RAI), Lorillard (LO) on Pending Deal
- Digital Ally (DGLY) Warns Lofty CEO Expectations May Not Be Attainable
EntreMed, Inc. (Nasdaq: ENMD) announced the initiation of a single-center Phase 2 study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma" at Princess Margaret Hospital where the study is led by Malcolm Moore, MD and Albiruni R.A. Razak, MD.
You May Also Be Interested In
- United Therapeutics (UTHR) Gains After Judge Rules Remodulin Patents are Not Invalid
- United Therapeutics (UTHR) Confirms Favorable Ruling in Remodulin Patent Case
- Rubicon Mineral (RBY) Reports Dismissal of Phoenix Gold Project Review
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!